NCT02730494View on ClinicalTrials.gov

Study Evaluating the Optimal Dosage for Equivalence Between Lcr Regenerans® Capsules and Tablets (Lactobacillus Rhamnosus Lcr35®) on the Vaginal Flora Colonisation

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2018

Conditions
Candidiasis, Vulvovaginal
Interventions
DEVICE

Lcr Regenerans® vaginal capsules

DEVICE

Lcr Regenerans® vaginal tablet

Trial Locations (1)

15000

BIOSE, Aurillac

Sponsors

Lead Sponsor

Biose
All Listed Sponsors
lead

Biose

INDUSTRY

NCT02730494 - Study Evaluating the Optimal Dosage for Equivalence Between Lcr Regenerans® Capsules and Tablets (Lactobacillus Rhamnosus Lcr35®) on the Vaginal Flora Colonisation | Biotech Hunter | Biotech Hunter